Dihexa as a nootropic: separating rat studies from human reality

What did @moistbreadcrumbs2.0 actually say?

The creator described Dihexa as an oligopeptide derived from angiotensin IV that can "increase cognitive markers" and "reverse cognitive impairment" in research settings. They credited it with reducing inflammatory cytokines IL-1β and TNF-α, signaling through the PI3K/AKT/mTOR pathway, and showing neuroprotective effects in an APP/PS1 Alzheimer's mouse model. To their credit, they ended with a genuine disclaimer: "there's not much research on it at all" and said it's "not something I would use myself to recommend to clients." That caveat matters more than it might seem, and we'll get into why.

The creator also made a minor slip at the end, calling this "part 3" while the caption also labels it Part 3, though they appeared to mean it as a continuation of a nootropic series. Minor inconsistency, nothing that changes the substance.

Does the science back this up?

Partially, but the evidence base is thin and almost entirely preclinical. The claims about PI3K/AKT signaling and cytokine reduction are grounded in real published work, but calling Dihexa a cognitive enhancer in any human-relevant sense is a stretch the data simply does not yet support.

The foundational research on Dihexa comes largely from Joseph Harding's lab at Washington State University. McCoy et al. (2013, Journal of Neurochemistry) reported that Dihexa outperformed BDNF in inducing spinogenesis and synaptogenesis in hippocampal cell cultures, and showed cognitive rescue in a scopolamine-impaired rat model. Benoist et al. (2021, Frontiers in Pharmacology) examined its effects in APP/PS1 transgenic mice and found reduced amyloid burden and preserved spatial memory, which is likely the study the creator referenced. Both are rodent or cell-culture studies. There are no published Phase I or II clinical trials in humans as of early 2025. The mechanistic story through HGF/c-Met receptor agonism and downstream PI3K/AKT is reasonably well-documented in vitro, but translating that to "reverses cognitive impairment" in people is a leap the existing data cannot make.

What did they get wrong, and what did they get right?

More right than wrong here, which is worth acknowledging plainly. The mechanistic description is largely accurate. Dihexa does appear to act as an HGF/c-Met receptor agonist and does signal through PI3K/AKT with downstream mTOR involvement. The anti-inflammatory cytokine data is real, at least in animal models.

Where the framing gets slippery is in phrases like "reverse cognitive impairment." That phrasing implies a degree of clinical certainty that preclinical mouse data simply cannot deliver. Reversing scopolamine-induced amnesia in a rat or rescuing spatial memory in a transgenic mouse is not the same as reversing cognitive impairment in a person. The creator does walk this back by expressing personal skepticism, but leading with "reverse cognitive impairment" without that qualifier upfront risks anchoring the viewer's takeaway in the stronger claim.

The creator also did not mention one significant concern: Dihexa's carcinogenic potential. McCoy et al. (2013) noted that because it promotes cell proliferation through c-Met agonism, there are legitimate oncological safety questions that have never been resolved in long-term human data. Omitting that is a real gap in an otherwise reasonably cautious video.

What should you actually know?

Dihexa is not approved by the FDA for any indication. It is not a supplement. It is not a clinically validated treatment. It is a research compound with an interesting mechanistic profile and zero human trial data. Anyone selling it for human use is operating in a legally and medically gray zone at best.

The PI3K/AKT/mTOR pathway the creator mentioned is not benign territory. That pathway is also implicated in tumor growth and proliferation. Compounds that activate it indiscriminately carry theoretical oncological risk, and without long-term safety data in humans, no one can tell you that risk is acceptable. This is not a fringe concern: it is the same reason mTOR activators are studied carefully in cancer biology.

If you are interested in neuroprotection or cognitive support, there are compounds with substantially more human evidence: omega-3 fatty acids, B-vitamin complexes in specific deficiency states, and lifestyle interventions like aerobic exercise all have randomized controlled trial data in humans. Dihexa does not. The creator's instinct to flag skepticism was correct. The missing piece was explaining why the safety unknowns matter as much as the efficacy unknowns.